Immuron IMRN Stock News

Immuron Limited (NASDAQ: IMRN) is flying in the market today with gains of more than 31%. The gains come after the company provided an update with regard to research and development agreements with the United States Department of Defense. Here’s the scoop:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

IMRN Runs For The Top On Research Update

In a press release offered up early this morning, Immuron announced an update with regard to cooperative research and development agreements with the United States Department of Defense.

The company was is working with the DoD to develop Travelan as a potential vaccine and treatment option for shigellosis and dysentary. The research involved a placebo controlled study of 12 juvenile rhesus monkeys that were segregated into 2 groups.

The first group included 8 subjects. These subjects were treated with Travelan. The second group included 4 subjects that were treated with a placebo.

All subjects were provided a twice daily treatment over the course of six days for a total of 12 doses. Three days later, the monkeys were exposed to ~3 x 109 viable Shigella organisms.

According to the press release, all of the animals in the placebo cohort displayed acute clinical signs of dysentery within 24 to 36 hours of exposure. However, on the Travelan-treated arm, only 2 of the 8 subjects showed signs of disentary. The remaining 75% of the treatment arm remained healthy, without any signs of dysentery following exposure.

Moreover, a histopathological analysis was performed, showing that all animals in the placebo group displayed severe inflammation in different parts of the gastrointestinal tract. These animals also had very high levels of inflammatory cytokines. Both of these measures are related to dysentery.

On the treatment arm, IMRN said that only 3 out of 8 subjects had signs of inflammation in the gastrointestinal tract. Also, only 2 of these animals had high levels of inflammatory cytokines in fecal samples.

As a result of this data, it is expected that Travelan is functionally cross-reactive and may have prophylactic activity against shigellosis. In a statement, Dr. Gray Jacob, CEO at IMRN, had the following to offer:

This is further validation of our technology platform. The work completed by our research collaborators at the WRAIR has clearly demonstrated the effectiveness of Travelan® and the Immuron technology platform in neutralizing pathogenic gastrointestinal bacterial infections and offers significant potential as a preventative treatment for US military personnel and civilians stationed or traveling in locations where such infections may be debilitating.

What This Means For The Company

At the end of the day, the news released by Immuron is huge for the company moving forward. After all, it means that Travelan is showing strong signs of efficacy in non-human primate models.

As such, the likely next move is a move into human trials. Once this takes place, it will set the stage for several events ahead that will likely act as catalysts. All in all, today marks a very important day for IMRN and the stock could see strong gains ahead as a result.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What Do You Think?

Where do you think IMRN is headed moving forward? Join the discussion in the comments below!

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.